Vetnuus | Desember 2023 14 « BACK TO CONTENTS Current evidence for non-pharmaceutical, non-surgical treatments of canine osteoarthritis <<< 13 D’Altilio et al. (2007) Double-blind, randomised, prospective, controlled study Placebo 10 mg active undenatured type-II collagen, 2000 mg glucosamine hydrochloride and 1600 mg chondroitin sulphate 2000 mg glucosamine hydrochloride and 1600 mg chondroitin sulphate 10 mg active undenatured type-II collagen 20 dogs 120 days followed by a 30-day withdrawal period Subjective: veterinary assessment by multiple VAS Objective: bodyweight, biochemical assay (creatinine, blood urea nitrogen, alanine aminotransferase and aspartate aminotransferase) Supplementing glucosamine hydrochloride, chondroitin sulphate with undenatured type-II collagen reduced overall pain, pain upon limb manipulation, and exercise induced lameness to a significant extent. Although this benefit was also lost following the 30-day treatment withdrawal period II Nutraceuticals with chondroitinglucosamine Chondroitin sulphate Dobenecker et al. (2002) See study details above under the omega-3 based nutraceuticals section Glucosamine hydrochloride and chondroitin sulphate Gupta et al. (2012) and D’Altilio et al. (2007) See study details above under the collagen-based nutraceuticals section McCarthy et al. (2007) Multi-centred double-blind, randomised prospective controlled study 475 mg/g glucosamine hydrochloride, 350 mg/g, chondroitin sulphate, 50 mg/g N-acetyl- d- glucosamine, 50 mg/ ascorbic acid and 30 mg/g of zinc sulphate Carprofen (2 mg/kg BID for 7 days followed by 2 mg/ kg SID for 63 days) 42 dogs 70 days Subjective: veterinary assessment via VAS Dogs treated with glucosamine hydrochloride and chondroitin sulphate+ showed statistically significant improvements in scores for pain, weight-bearing and severity of the condition by day 70. Slower onset of clinical response than for carprofen-treated dogs II VACCINATION BOOKS The LAST ORDERS for 2023 for vaccination books will be 30 November. No orders will be accepted after this – this is to ensure that stock will be dispatched by 15 December 2023. Orders for 2024 will resume on 16 January. To order/for more information contact Debbie Breeze on 012 346 1150 or debbie@sava.co.za Nutraceutical category investigated Nutraceutical compound investigated Author Study type Groups Sample size Study length Outcome measures Conclusions Evidence level (Aragon & Budsberg 2005) Tabel 2 continued
RkJQdWJsaXNoZXIy OTc5MDU=